Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SPCX
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5201
iShares ESG Advanced MSCI EAFE ETF
DMXF
$963M
| $805K | ﹤0.01% |
9,516
+429
| +5% | +$35.1K |
|
5202
GeoPark
GPRK
$638M
| $804K | ﹤0.01% |
88,333
-60,305
| -41% | -$587K |
|
5203
Pacific Biosciences
PACB
$435M
| $803K | ﹤0.01% |
477,776
-1,362,685
| -74% | -$1.98M |
|
|
AGEN
5204
Agenus
AGEN
$345M
| $802K | ﹤0.01% |
262,068
-33,753
| -11% | -$121K |
|
|
ATYR
5205
aTyr Pharma
ATYR
$53M
| $802K | ﹤0.01% |
1,343,636
+118,169
| +10% | +$77.2K |
|
5206
Nuveen Minnesota Quality Municipal Income Fund
NMS
$70.2M
| $802K | ﹤0.01% |
66,197
+2,500
| +4% | +$30.5K |
|
5207
ProShares UltraPro Short QQQ
SQQQ
$1.82B
| $801K | ﹤0.01% |
22,048
+14,521
| +193% | +$701K |
|
5208
Akebia Therapeutics
AKBA
$243M
| $800K | ﹤0.01% |
701,540
+120,213
| +21% | +$143K |
|
|
WEEL
5209
Peerless Option Income Wheel ETF
WEEL
$41.5M
| $797K | ﹤0.01% |
+40,152
| New | +$812K |
|
|
ORBS
5210
Eightco Holdings
ORBS
$312M
| $797K | ﹤0.01% |
1,146,107
+19,229
| +2% | +$17.3K |
|
5211
InnovAge Holding
INNV
$1.47B
| $796K | ﹤0.01% |
67,174
+44,100
| +191% | +$361K |
|
5212
FT Energy Income Partners Strategy ETF
EIPX
$581M
| $795K | ﹤0.01% |
25,405
+205
| +0.8% | +$6.55K |
|
5213
Crawford & Co Class A
CRD.A
$623M
| $793K | ﹤0.01% |
70,321
+2,622
| +4% | +$27.9K |
|
5214
Virtus Biotech Clinical Trials ETF
BBC
$50.6M
| $792K | ﹤0.01% |
15,026
-210
| -1% | -$9.37K |
|
5215
Sagimet Biosciences
SGMT
$656M
| $790K | ﹤0.01% |
102,227
+8,920
| +10% | +$60.7K |
|
5216
John Marshall Bancorp
JMSB
$324M
| $790K | ﹤0.01% |
36,244
+14,945
| +70% | +$317K |
|
5217
Lightbridge
LTBR
$283M
| $790K | ﹤0.01% |
89,863
-99,965
| -53% | -$1.13M |
|
5218
Outset Medical
OM
$74.1M
| $786K | ﹤0.01% |
181,983
+12,540
| +7% | +$54.9K |
|
|
FRMM
5219
Forum Markets
FRMM
$77.3M
| $785K | ﹤0.01% |
144,535
-7,108
| -5% | -$31.1K |
|
5220
Invesco Global ex-US High Yield Corporate Bond ETF
PGHY
$226M
| $782K | ﹤0.01% |
39,676
-335
| -0.8% | -$6.63K |
|
5221
Domo
DOMO
$182M
| $781K | ﹤0.01% |
249,425
-465,675
| -65% | -$1.56M |
|
5222
iShares MSCI BIC ETF
BKF
$75.3M
| $770K | ﹤0.01% |
19,868
-1,448
| -7% | -$59.5K |
|
5223
Fidelity Small-Mid Multifactor ETF
FSMD
$2.54B
| $769K | ﹤0.01% |
14,548
+10,280
| +241% | +$508K |
|
5224
Global X Autonomous & Electric Vehicles ETF
DRIV
$373M
| $768K | ﹤0.01% |
19,920
+4,551
| +30% | +$172K |
|
5225
American Coastal Insurance
ACIC
$449M
| $768K | ﹤0.01% |
69,183
-47,383
| -41% | -$523K |
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 423 new, 3,809 increased, 3,216 reduced and 305 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 423 new positions and closed 305 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.